Peoples Bank OH Has $320,000 Position in Amgen Inc. (NASDAQ:AMGN)

Peoples Bank OH decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 13.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 993 shares of the medical research company’s stock after selling 158 shares during the period. Peoples Bank OH’s holdings in Amgen were worth $320,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently made changes to their positions in AMGN. Hershey Financial Advisers LLC bought a new position in Amgen during the second quarter worth $30,000. nVerses Capital LLC acquired a new stake in Amgen during the 2nd quarter worth about $31,000. Bbjs Financial Advisors LLC bought a new position in shares of Amgen in the 2nd quarter worth about $33,000. Matrix Trust Co acquired a new position in shares of Amgen in the 3rd quarter valued at about $36,000. Finally, FSA Wealth Management LLC boosted its position in shares of Amgen by 182.0% during the 1st quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock valued at $40,000 after purchasing an additional 91 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Up 0.3 %

Amgen stock opened at $315.69 on Friday. Amgen Inc. has a fifty-two week low of $249.70 and a fifty-two week high of $346.85. The company has a debt-to-equity ratio of 9.64, a quick ratio of 0.89 and a current ratio of 1.26. The firm’s 50-day simple moving average is $325.77 and its 200 day simple moving average is $313.12. The stock has a market cap of $169.35 billion, a PE ratio of 45.10, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61.

Amgen (NASDAQ:AMGN) last announced its earnings results on Tuesday, August 6th. The medical research company reported $4.97 earnings per share for the quarter, missing analysts’ consensus estimates of $5.01 by ($0.04). The business had revenue of $8.39 billion during the quarter, compared to analysts’ expectations of $8.35 billion. Amgen had a return on equity of 161.72% and a net margin of 10.12%. Amgen’s quarterly revenue was up 20.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.00 EPS. Research analysts predict that Amgen Inc. will post 19.49 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Tuesday, August 6th. Stockholders of record on Friday, August 16th were given a dividend of $2.25 per share. This represents a $9.00 annualized dividend and a dividend yield of 2.85%. The ex-dividend date of this dividend was Friday, August 16th. Amgen’s dividend payout ratio is presently 128.57%.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on AMGN. TD Cowen lifted their target price on Amgen from $381.00 to $383.00 and gave the stock a “buy” rating in a report on Monday. Oppenheimer reiterated an “outperform” rating and issued a $380.00 price objective on shares of Amgen in a research note on Wednesday, August 7th. Robert W. Baird reiterated an “underperform” rating and set a $215.00 target price on shares of Amgen in a research report on Wednesday, September 25th. Argus raised their price target on shares of Amgen from $300.00 to $340.00 and gave the stock a “buy” rating in a report on Thursday, June 27th. Finally, Royal Bank of Canada reiterated an “outperform” rating and set a $362.00 price objective on shares of Amgen in a report on Thursday, September 26th. One analyst has rated the stock with a sell rating, eleven have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Amgen has an average rating of “Moderate Buy” and an average target price of $332.55.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.